• Huma Qureshi
  • Ambreen Arif
  • Ejaz Alam


Objective: To see effect of Lamivudine on sero conversion of HBeAg positive cases co infectedwith Delta hepatitis. Methods: Hepatitis B positive patients with deranged liver functions for 6months were tested for HBeAg, HBV DNA and anti-Delta virus (HDV), using ELISA. Patientswere divided into 2 groups, group 1: HBeAg, HBV DNA positive (wild type) but delta negativeand group 2: HBeAg, HBV DNA positive (wild type) with delta positive. Lamivudine (100 mg)was advised to both groups till sero-conversion. Results: Of 124 cases in year 1999–2005, 69were in (Group 1), and 55 were in (Group 2). Eighty percent were males in both groups. ALTnormalisation occurred in 75%, 24% cases within 6 months respectively. At the start of therapymean HBeAg was 289±189 in group 1 and 142±160 in group 2. With treatment, the values did notchange much till 12 months of therapy. The fall was significantly slow in delta positive cases. At36 months 26 (38%) cases in group 1 and 9 (16.4%) cases in group 2 sero-converted. Nine casesin each group remained non-responders while 2 in each group relapsed. Conclusion: Wild type ofHBV/HDV co-infected cases have a 16% chance of seroconversion which negates the concept thatonce infected with delta virus there is not much that can be done.Keywords: Hepatitis B virus, Delta hepatitis, co-infection, sero-conversion, fulminant hepatitis,lamuvidine, interferon, entecavir



Andre F. Hepatitis B epidemiology in Asia: the Middle East

and Africa Vaccine 2000;18 (Suppl 1):s20–2.

Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, et al.

Epidemiology and clinical pattern of hepatitis Delta virus

infection in Pakistan. J Gastroenterol Hepatol 2005;20:1503–7.

Zuberi SJ. International Hepatology Communication 5


Lau DT, Doo E, Park Y, Kleiner DF, Schmid P, Mary C.

Kuhns MC, et al. Lamuvidine for chronic Delta

hepatitis.Hepatology 1999;30(2):579–81.

Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C,

Rubin M. A preliminary trial of lamivudine for chronic

hepatitis B infection. N Engl J Med 1995;333:1657–61.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL,

Goodman Z, et al. US Lamivudine Investigator Group.

Lamivudine as initial treatment for chronic hepatitis B in the

United States. New England. J Med 1999;341:1256–63.

Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt

C, et al. Prevalence and clinical correlates of YMDD variants

during lamivudine therapy for patients with chronic hepatitis B.

Clin Infect Dis 2003;36:687–96.

Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and

safety of 5-years Lamivudine treatment of Chinese patients

with chronic hepatitis B. J Gastroenterol Hepatol

;16(suppl 1):A60.

Lai C-L, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C,

et al. Prevalence and clinical correlates of YMDD variants

during lamivudine therapy of patients with chronic B. Clin

Infect Dis 2003;36:687–96.

Locarnini S. Hepatitis B viral resistance: mechanisms and

diagnosis. J Hepatol 2003;39:S124–S132.

Four year data on Entecavir Resistance in Nucleoside–naïve

patients with chronic hepatitis B. 42nd EASL Conference April

–15, 2007, Barcelona, Spain.

Leung N, Sherman M, Peng CY, Entecavir (ETV) Results in

Higher HBV- DNA Reduction vs Adefovir (ADV) in

Chronically Infected HBeAg+ Antiviral-Naive Adults: 48-Week

Results (EARLY Study). Digestive Disease Week 2007 (DDW

. Washington, DC. May 19–24, 2007. Abstract S-1773.

H, Arif A, Ahmed W, Alam E. YMDD Mutation in Pakistani

Patients. The comparison of Eastern Response with the

Western Response (unpublished data) presented in PSG

Congress 2006 Karachi.

Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS,

Heathcote J. Effect of alpha-treatment in patients with hepatitis

B e antigen-positive chronic hepatitis B. A meta-analysis. Ann

Intern Med 1993;119:312–23.

Krossgaard K, Bindslev N, Christensen E, Craxi A, Schlichting

P, Schalm S, et al. The treatment effect of alpha interferon in

chronic hepatitis B is independent of pre-treatment variables.

Results based on indivigual patient data from 10 clinical

controlled trials. European Concerted Action on Viral Hepatitis

(Eurohep). J Hepatol 1994;21:646–55.